![Microbiology / Tuberculosis treatment / Latent tuberculosis / Isoniazid / Pyrazinamide / AIDS / Rifampicin / Directly Observed Therapy – Short Course / Multi-drug-resistant tuberculosis / Tuberculosis / Medicine / Health Microbiology / Tuberculosis treatment / Latent tuberculosis / Isoniazid / Pyrazinamide / AIDS / Rifampicin / Directly Observed Therapy – Short Course / Multi-drug-resistant tuberculosis / Tuberculosis / Medicine / Health](https://www.pdfsearch.io/img/664cdb333f5c8eba5ab146f6cb1eb890.jpg)
| Document Date: 2014-07-21 13:52:24 Open Document File Size: 73,05 KBShare Result on Facebook
City Princeton / Sellersville / London / Marietta / / Company Teva Pharmaceuticals / VersaPharm Incorporated / WHO Press / Sandoz Inc. / INH / / Continent America / / Country United States / / Facility Royal College of Physicians / National Institute / / IndustryTerm pharmaceutical / / MedicalCondition TB / disease / TB disease / INH- or RIFresistant M. tuberculosis / active tuberculosis / active TB / latent TB infection / tuberculosis disease / diseases / severe illness / HIV/AIDS / infection / Infectious Disease / injuries / tuberculosis / latent Mycobacterium tuberculosis infection / / MedicalTreatment antiretroviral treatment / Directly observed therapy / / Organization World Health Organization / Food and Drug Administration / CDC / Institute for Health / Centers for Disease Control and Prevention / / Person Joann Schaefer / / / Position Chief Medical Officer / Family/Internal/General / M.D. Chief Medical Officer / / Product levofloxacin / pyrazinamide / INH / Isoniazid / Rifampin / / ProvinceOrState Nebraska / New Jersey / Pennsylvania / Georgia / / PublishedMedium Morbidity and Mortality Weekly Report / / URL http /
SocialTag |